Idiopathic pulmonary fibrosis: Nintedanib
The effects, mechanism of action and clinical trials for nintedanib as a treatment for IPF.
Nintedanib is an approved pharmacological agent for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This video explains the effects, mechanism of action and clinical trials for nintedanib.
[Please complete our feedback form]
Demystifying Medicine, Education, Idiopathic pulmonary fibrosis (IPF)
Related News
News Listing
Daily News ➚
5 McMaster students named McCall MacBain International Fellows
Collaborations & Partnerships, Education, Funding
3 days ago
Department of Pediatrics ➚
Behind the White Coat: A conversation with pediatric neurology resident Hannah Snyder
Education, Feature
6 days ago